Articles from Biocon Limited

Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the commercial launch of Yesafili™ (aflibercept-jbvf) in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously and granted interchangeable designation* by the U.S. Food and Drug Administration in May 2024, allowing substitution at the pharmacy level in accordance with state laws.

Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the publication of two important clinical studies supporting the effectiveness of Yesafili™ (aflibercept-jbvf). The clinical data from the Phase III INSIGHT program evaluating MYL‑1701P, its aflibercept biosimilar, was published in two peer-reviewed journals, contributing to the clinical evidence base supporting the development of aflibercept MYL‑1701P for the treatment of diabetic macular edema (DME). MYL-1701P was approved and the vial format was granted interchangeable designation under the name Yesafili™ by the U.S. Food and Drug Administration in May 2024.

Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the commercial launch of Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab-kyqq) in the United States. Bosaya™ (biosimilar to Prolia®) and Aukelso™ (biosimilar to Xgeva®) are now available by prescription nationwide through specialty pharmacies and healthcare providers. Both products have been previously approved and granted interchangeable designation by the U.S. Food and Drug Administration in September 2025, allowing substitution at the pharmacy level in accordance with state laws.

Biocon Limited (BSE: 532523; NSE: BIOCON) today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026, following approvals from the Nomination & Remuneration Committee and the Board of Directors. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the Company’s ability to operate at scale and compete effectively in global markets.